Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs).
Passkey has raised $20.0M in total funding. The most recent round was Seed. The last funding was announced in October 2024.
Passkey's investors include Breakout Ventures, Bison Ventures, Alexandria Venture Investments, GRIDS Capital, Innovation Endeavors.
Passkey is headquartered in Cambridge, United States.
Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs).
Passkey is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Passkey — Funding & Investors." VCBacked, October 22, 2024, https://www.vcbacked.co/company/passkey. Accessed July 21, 2026.
VCBacked. (2024). Passkey — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/passkey
{{cite web |title=Passkey — Funding & Investors |url=https://www.vcbacked.co/company/passkey |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated